Related Experiment Video

Updated: Apr 3, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Pacritinib: a new agent for the management of myelofibrosis?

Yan Beauverd1, Donal P McLornan1,2, Claire N Harrison3

  • 1a 1 Guy's and St. Thomas' NHS Foundation Trust, Department of Haematology , London, UK.

Expert Opinion on Pharmacotherapy
|September 22, 2015
PubMed
Abstract

Insights

Pacritinib, a novel Janus kinase (JAK) inhibitor, shows promise in treating myelofibrosis (MF) by managing symptoms and spleen size. It may offer a better side-effect profile, especially for patients with anemia and low platelets, compared to ruxolitinib.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myelofibrosis (MF) is a clonal hematological disorder driven by specific gene mutations.
  • Constitutive activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription pathway is a hallmark of MF.
  • Janus kinase inhibitors (JAKIs) have transformed MF treatment, with ruxolitinib being the sole approved agent.

Purpose of the Study:

  • To summarize the development and clinical trial results of pacritinib, a novel JAK2 and FLT3 inhibitor.
  • To present current efficacy and safety data for pacritinib in myelofibrosis.
  • To indirectly compare pacritinib with ruxolitinib based on available data.

Main Methods:

  • Review of preclinical data and Phase I-III clinical trials for pacritinib.
  • Analysis of efficacy and safety outcomes from pacritinib studies.
  • Indirect comparative analysis with ruxolitinib.

Main Results:

  • Pacritinib exhibits a distinct kinome target profile compared to ruxolitinib.
  • Pacritinib effectively controls myelofibrosis-related symptoms and splenomegaly.
  • Pacritinib demonstrates a potentially favorable safety profile regarding hematological side effects compared to ruxolitinib.

Conclusions:

  • Pacritinib is a promising agent for managing myelofibrosis, particularly for patients with anemia and thrombocytopenia.
  • Its distinct target profile and tolerability make it suitable for combination therapies.
  • Pacritinib represents a valuable therapeutic option in the evolving landscape of myelofibrosis treatment.
Keywords:
Janus kinase inhibitorsmyelofibrosismyeloproliferative diseasepacritinibruxolitinibtreatment

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
651
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
609
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
950
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
684
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
620
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
583